Free Trial

Athira Pharma (ATHA) Competitors

Athira Pharma logo
$0.37 +0.04 (+12.09%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.38 +0.01 (+3.24%)
As of 06:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATHA vs. ABVC, CUE, GANX, ATRA, RNXT, RENB, ZIVO, QNTM, CRVO, and AADI

Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include ABVC BioPharma (ABVC), Cue Biopharma (CUE), Gain Therapeutics (GANX), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), Renovaro (RENB), ZIVO Bioscience (ZIVO), Quantum Biopharma (QNTM), CervoMed (CRVO), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

Athira Pharma vs. Its Competitors

ABVC BioPharma (NASDAQ:ABVC) and Athira Pharma (NASDAQ:ATHA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

ABVC BioPharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500.

In the previous week, Athira Pharma had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.14 beat Athira Pharma's score of -0.65 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
ABVC BioPharma Positive
Athira Pharma Negative

Athira Pharma has a consensus target price of $11.25, suggesting a potential upside of 2,940.54%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ABVC BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Athira Pharma
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Athira Pharma has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. ABVC BioPharma's return on equity of -29.62% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
ABVC BioPharma-963.46% -29.62% -14.08%
Athira Pharma N/A -142.99%-106.40%

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by company insiders. Comparatively, 19.8% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ABVC BioPharma has higher revenue and earnings than Athira Pharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABVC BioPharma$510K157.81-$4.90M-$0.13-36.46
Athira PharmaN/AN/A-$96.94M-$2.07-0.18

Summary

Athira Pharma beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHA vs. The Competition

MetricAthira PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.89M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E Ratio-0.1820.8027.0020.11
Price / SalesN/A286.27429.45119.84
Price / CashN/A41.1936.8257.86
Price / Book0.327.487.985.56
Net Income-$96.94M-$55.04M$3.16B$248.40M
7 Day Performance22.88%2.44%2.38%4.67%
1 Month Performance11.78%1.90%2.17%6.64%
1 Year Performance-89.09%4.35%33.80%21.31%

Athira Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATHA
Athira Pharma
2.4758 of 5 stars
$0.37
+12.1%
$11.25
+2,940.5%
-85.9%$12.89MN/A-0.1840
ABVC
ABVC BioPharma
0.6794 of 5 stars
$3.99
+28.3%
N/A+521.2%$52.81M$510K-30.6930Positive News
Gap Up
High Trading Volume
CUE
Cue Biopharma
4.073 of 5 stars
$0.70
+0.7%
$3.00
+328.4%
-25.0%$52.38M$9.29M-1.0560
GANX
Gain Therapeutics
2.8397 of 5 stars
$1.60
-5.3%
$8.20
+412.5%
+50.0%$50.61M$50K-1.8620News Coverage
Positive News
ATRA
Atara Biotherapeutics
4.0952 of 5 stars
$8.58
+1.3%
$17.75
+106.9%
+16.5%$50.46M$128.94M-2.31330
RNXT
RenovoRx
2.8698 of 5 stars
$1.32
-2.9%
$7.25
+449.2%
+7.4%$49.74M$240K-3.306
RENB
Renovaro
0.9836 of 5 stars
$0.30
+2.6%
N/A-80.1%$49.72MN/A-0.3920Gap Down
ZIVO
ZIVO Bioscience
N/A$13.00
+8.4%
N/A+85.9%$49.62M$15.85K-2.6610Gap Up
QNTM
Quantum Biopharma
N/A$16.56
-2.9%
N/AN/A$49.60MN/A-1.04N/A
CRVO
CervoMed
3.3123 of 5 stars
$5.87
+3.9%
$27.63
+370.6%
-59.2%$49.17M$9.74M-2.694News Coverage
Positive News
AADI
Aadi Bioscience
0.6374 of 5 stars
$1.99
+5.9%
$1.67
-16.2%
+44.5%$49.15M$25.07M-0.8740

Related Companies and Tools


This page (NASDAQ:ATHA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners